Professor Paul Maruff, Chief Scientific Officer
Professor Paul Maruff is one of the founders of CogState. He is a Professor in the School of Psychological Science at La Trobe University, Melbourne. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction.
Paul's research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to identify subtle neurocognitive impairment, and to assess the efficacy of pharmacological treatment, in Alzheimer's disease, mild cognitive impairment and the HIV dementia complex. He has also used this approach to identify neurocognitive dysfunction, and monitor treatment efficacy in psychiatric disease such as schizophrenia, obsessive-compulsive disorder and depression in adults and attention deficit disorder, developmental dyspraxia, and substance abuse in children.
Paul has published over 100 research articles in international peer-reviewed scientific journals, and has co-authored 10 book chapters and review articles.
Assoc. Professor David Darby, Chief Medical Officer
Associate Professor David Darby MBBS, PhD, FRACP is a founder of CogState. He graduated in Medicine at the University of Melbourne in 1981, completing a PhD in neurology and neuropsychology in 1990 and his neurology training in 1991. He served as an instructor in Behavioral Neurology at Beth Israel Hospital, Harvard Medical School from 1992 to 1995. He was Chairman of the Memory Disorders Service at the Repatriation Campus of the Austin & Repatriation Medical Centre from 1997 to 2000.
David has published over 40 research papers in international peer-reviewed scientific journals and has co-authored a neuropsychological textbook. He is a Director of the Behavioral Neurology Laboratory at the Mental Health Research Institute of Victoria.
Dr. John Harrison, Principal Scientist
Dr John Harrison is a neuropsychologist with more than 20 years commercial experience and expertise in neuropsychological assessment gained during post-doctoral research fellowships at Cambridge University and Charing Cross & Westminster Medical School. John has assisted more than 40 pharmaceutical companies in successfully selecting and integrating cognitive testing into clinical drug trials and has presented on CNS outcome measures at numerous investigator meetings throughout Europe, Japan, Australia, Canada, the United States and South America.
John has published more than 40 scientific articles, and a neuroscience book ‘Synaesthesia: The Strangest Thing'.
Professor Peter Snyder, Science Lead: USA
Professor Peter Snyder, PhD, received his doctorate in clinical psychology and behavioral neuroscience, from Michigan State University in 1992. He received a fellowship in 1992 from the Epilepsy Foundation of America, and has served as an NIMH Clinical Neurosciences Fellow and as an NIH visiting scientist. Until late 2005, as a Director and Early Clinical Leader at Pfizer Global Research & Development - Groton Laboratories, Peter led the early clinical development of novel compounds for the treatment of schizophrenia and Alzheimer's disease for Pfizer Inc.
After seven years at Pfizer, Peter left for his current post as a tenured Professor in the Department of Psychology (Neuropsychology & Cognitive Neuroscience) at the University of Connecticut. He acts as a consultant for CogState. Peter is a Fellow of the American Psychological Association, is Associate Editor of Brain and Cognition, has published over 120 peer-reviewed articles, has delivered over 100 presentations at international scientific conferences, and is the Senior Editor of a best-selling handbook on clinical neuropsychological practice.
Assistant Professor Angela F. Caveney, Consultant, Project Manager: USA
is a licensed psychologist and member of the research faculty at the University of Michigan Medical School. She completed her Ph.D. in clinical psychology at Central Michigan University, her clinical residency training at the Veteran's Hospital in Dayton, Ohio, and her post doctoral fellowship in clinical neuropsychology at the University of Michigan. Angela is the recipient of a NIH K23 early career award focused on examining cognition following treatment of unruptured brain aneurysms. Her research interests include measurement of change in cognition following use of drugs, devices and surgical interventions in patients with neurodegenerative disorders and neurological emergencies.
